Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematological cancer usually involving skin and/or bone marrow. Recent molecular evidence suggests that BPDCN originates from the myeloid lineage. Short-term responses to conventional treatments underline the need for new therapies in this disease. We present the case of a 55-year-old woman with therapy-related leukemic-phase BPDCN who experienced a six month remission following clofarabine-based chemotherapy treatment. Intensive anthracyclin-based regimen and stem-cell transplant (SCT) were excluded due to pre-existing severe cardiac dysfunction. Relapse occurred after six month of complete remission and the patient died from thrombocytopenia-induced intracranial bleeding. For elderly or young PBDCN patients not eligible for intensive regimen or in relapsed/refractory disease, clofarabine-based therapy appears as a suitable option.
Introduction
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive hematological malignancy derived from plasmacytoid dendritic cells, recognized as a separate entity since the 2008 WHO classification [1] . This disease is usually revealed by skin lesions (brownish to violaceous infiltrated 'bruise-like' patches, plaques or tumours), possibly associated to splenomegaly, lymphadenopathy, and variable bone marrow or blood involvement [2, 3] . A minority of patients presents with pure leukemic disease [4] . Phenotypic characterization usually shows positivity for CD4, CD56, CD123, blood dendritic cell antigen (BDCA)2, T-cell leukaemia/lymphoma (TCL)1 and B-cell chronic lymphocytic leukaemia/lymphoma (BCL)11A expression [5] . A range of cytogenetic alterations are reported in PBDCN with a predominance of deletions involving chromosomes 5q (72%), 12p and 13q (64%), 6q (50%), 15q (43%) and 9 (28%) [6] . The prognosis is dismal with a median overall survival of twelve to heighten months in case of pure skin involvement [3, 7] and only height month in leukemic forms of PBDCN [4] .
Case report
A 55-year-old woman presented with anemia and alteration of general state. She had history of resolved with age-related limitation for intensive therapy and also in relapsed or refractory AML in younger patients [12] [13] [14] . Because of severe cardiac dysfunction, intensive anthracyclin-based regimen and SCT were excluded in our patient. We aimed to treat her with a clofarabine-based AML-like regimen, which induced a complete remission. To explain the importance of therapy-related side effects, we hypothesized that previous chemotherapy given for lymphoma and diabetes contributed to immune dysfunction and related infections. Concomitant use of dexamethasone to reduce clofarabine-induced side effects may also have contributed to immunodeficiency. We used AML-like regimen based on an expected reduced toxicity compared to intensive ALL-like treatments and due to recent evidence of genetic lesions in IKAROS family of genes (IKZF1, IKZF2, IKZF3), HOXB9, UBE2G2, ZEB2 and TET2 genes -mostly documented in myeloid neoplasms -in PBDCN [15] . Achievement of a six-month-length remission in our patient following clofarabine-based treatment is similar to the observations made in leukemic-phase patients treated with intensive regimens (excluding SCT) [4, 7] . We suggest that clofarabine/cytarabine combination may be an option in unfit PBDCN patients or in case of relapsed/refractory disease to allow subsequent SCT.
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